DKK1 promotes hepatocellular carcinoma cell migration and invasion through β-catenin/MMP7 signaling pathway
© Chen et al.; licensee BioMed Central Ltd. 2013
Received: 31 July 2013
Accepted: 3 December 2013
Published: 10 December 2013
Recently several reports have indicated that elevated expression of DKK1 is tightly associated with the progression of hepatocellular carcinoma (HCC). However, the biological function of DKK1 in HCC has not yet been well documented.
In this study, the role of DKK1 in tumor cell proliferation, migration and invasion was investigated using MTT, colony formation, wound scratch, transwell assays, and also human HCC samples.
Both gain- and loss-of-function studies showed that DKK1 did not influence the tumor cell proliferation and colony formation, while dramatically promoted HCC cell migration and invasion. Subsequent investigations revealed that β-catenin was an important target of DKK1. The blocking of β-catenin by pharmacological inhibitor antagonized the function of DKK1, whereas introduction of β-catenin by transfection with plasmids or treatment with GSK3β inhibitor phenocopied the pro-migration and pro-invasion effects of DKK1. We further disclosed that DKK1 exerted its pro-invasion function, at least in part, by promoting β-catenin expression, in turn, upregulating the expression of matrix metalloproteinase 7 (MMP7), which was independent of the canonical Wnt signaling pathway. Moreover, introduction of MMP7 significantly enhanced the ability of HCC cells to invade extracellular matrix gel in vitro. Consistently, in human HCC tissues, DKK1 level was positively correlated with β-catenin expression, as well as tumor metastasis.
Taken together, these results demonstrated that DKK1 is overexpressed in HCC; moreover, ectopic expression DKK1 promotes HCC cell migration and invasion at least partly through β-catenin/MMP7 signaling axis, suggesting that DKK1 may be a promising target for HCC therapy.
Hepatocellular carcinoma (HCC) is one of the most commonly diagnosed cancers, ranking as the third leading cause of all cancer-related death in the world . Despite some advances in early detection and the use of modern surgical techniques in combination with various treatment modalities, such as radiotherapy and chemotherapy, to date, the prognosis of the patients with HCC still remains poor. It has been shown that only 30%-40% of patients are amenable to potentially curative therapies, because most patients are often at advanced stage of disease at the time of diagnosis . Moreover, the overall 5-year survival rate of HCC patients remains unsatisfactory, mainly because of a high incidence of recurrence and metastasis after hepatic resection . It is well-believed that elucidation of the underlying molecular basis involved in HCC progression and metastasis is very important for the development of effective HCC therapeutic agents. In order to improve HCC treatments and outcomes, therefore, identifying the potential molecules that promote HCC progression and metastasis are urgently needed.
Dickkopf1 (DKK1), a secreted protein involved in head formation in embryonic development, binds to the low-density lipoprotein receptor-related protein-5/6 (LRP5/6) Wnt co-receptor and prevents the formation of active Wnt-Frizzled-LRP5/6 receptor complexes, thus blocking the canonical Wnt/β-catenin signaling pathway . Numerous studies have shown that DKK1 was implicated in the control of various pathological and physiological processes, including adult hippocampal neurogenesis , osteoclastogenesis , tumor cell proliferation, survival, migration and invasion [7, 8]. However, the role of DKK1 in tumor biology is controversial. Several studies have shown that DKK1 can either inhibit or promote tumor progression and metastasis. On one hand, DKK1 has been shown to inhibited tumorigenesis. For example, González-Sancho et al. found that DKK1 expression decreases in human colon tumors, suggesting that DKK1 may act as a tumor suppressor gene in this neoplasia . Indeed, up-regulation of DKK1 causes a decrease in colon cancer cell proliferation, clonogenicity, migration, and invasiveness [10, 11]. On the other hand, overexpression of DKK1 was found in 126 out of 180 human non-small cell lung cancers, 59 of 85 small cell lung cancers, and 51 of 81 esophageal squamous cell carcinomas patients . High expression of DKK1 has also been reported in breast and kidney cancers . A recent research article showed that high expression of DKK1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma (ICC) patients after surgery, vice versa, depletion of DKK1 using small interfering RNA results in a decrease in ICC cell migration and invasion . Taken together, all these findings suggest that DKK1 performs an oncogenic or a tumor-suppressing function depends on the cell type or context.
Several years ago, Qin et al. reported that overexpression of DKK1 by transfection is able to inhibit the growth and migration. But vice versa, reduction of DKK1 expression by RNA interference is able to increase the migration in a model of hepatocellular carcinoma cells . However, recently several research studies indicated that elevated expression of DKK1 was found in both tissue and serum samples from patients with HCC [15–17]. Moreover, overexpression of DKK1 not only enhances the tumor formation efficiency and tumor growth but also promotes the cell invasion and metastasis in vitro and in vivo, whereas knockdown of DKK1 significantly reduced both migratory and invasive abilities of HCC cells [15, 17]. Therefore, whether DKK1 is an oncogene or a tumor suppressor in HCC remains to be further investigated. Furthermore, the precise mechanism of DKK1 involved in tumorigenesis has not been well-documented.
In this present study, both gain- and loss-of-function studies showed that DKK1 did not influence HCC cell proliferation and colony formation, while dramatically promoted HCC cell migration and invasion. We further confirmed that DKK1 exerted its pro-invasion function, at least in part, by promoting β-catenin expression, in turn, upregulating the expression of matrix metalloproteinase 7 (MMP7), which was independent of the canonical Wnt signaling pathway. Moreover, introduction of MMP7 significantly enhanced the ability of HCC cells to invade extracellular matrix gel in vitro. Our findings highlight the oncogenic role of DKK1 in promoting HCC cell migration and invasion through activation of β-catenin/MMP7 signaling pathway, implicating that DKK1 may serve as a potential target for HCC therapy.
Materials and methods
3-(4, 5-dimethylthiazol)-2, 5-diphenyltetrazolium bromide (MTT), Hoechst33342, G418 and LiCl were purchased from Sigma (St. Louis, MO, USA). RPMI 1640 and fetal calf serum (FCS) were purchased from Gibco (Grand Island, NY, USA). The sources of primary antibodies used for Western blot: DKK1 (cat. sc-25516), LRP6 (cat. sc-17982), GSK3β (cat. sc-53931), β-catenin (cat. sc-7199) and MMP7 (cat. sc-101566) as well as the corresponding horseradish peroxidase-conjugated second antibodies were all purchased from Santa Cruz Biotechnologies (Santa Cruz, CA, USA). Cy3-labeled goat anti-mouse second antibody was purchased from Beyotime Institute of Biotechnology (cat. A0521, Shanghai, China). All other chemicals used in this study were commercial products of reagent grade.
Human tissue specimens and cell lines
Human HCC (30 cases of primary, 41 cases of metastasis) and adjacent non-tumor liver tissues were collected from 71 patients undergoing resection of HCC at the Huai-He Hospital, Henan University (Kaifeng, China). All tissues were classified according to the tumor-node-metastasis classification system of the union for International Cancer Control. Informed consent was obtained from each patient, and the study was approved by the Institute Research Ethics Committee at the hospital.
Cell lines, derivative from human HCC (HepG2, SMMC7721, Huh7 and Bel7402) and normal liver cell line (QSG-7701) were used in this study. All of them were purchased from the cell bank of the Chinese Academy of Science (Shanghai, China), these cells were maintained in RPMI1640 medium containing 10% fetal calf serum, 100 units/mL penicillin, and 100 μg/mL streptomycin, at 37°C in a humidified incubator containing 5% CO2.
The full-length coding region (801 bp) of DKK1 was amplified from human genomic DNA by reverse transcription-polymerase chain reaction (RT-PCR) using the following primers: DKK1-sense 5′-CCG CTC GAG ATG ATG GCT CTG GGC GCA GCGGG-3′, and antisense 5′-CGG GAT CCG CTG GTT TAG TGT CTC TGA CAAGT-3′, then the PCR products were digested with XhoI/BamHI and were inserted into the pIRES2-EGFP vector (Clontech).The recombinant construct was verified by direct DNA sequencing.
For the construction of siRNA expression plasmids, A siRNA sequence targeted human DKK1 transcript (accession no. NM_012242.2; sense 5′-GGAATAAGTACC AGACCATTG-3′) was selected for RNA interference (RNAi). This sequence showed no homology with other known human genes. A scrambled sequence (sense 5′-GGAATAAGACCATGACCATTG-3′), which is no homologous to any human DNA sequence, served as a negative control. Two complementary oligonucleotides that contain both sense and antisense siRNA sequences, the loop sequence (5′-TTCAAGAGA-3′) and the flanking Bam H I and Eco R I sites were synthesized chemically. Then these two complementary oligonucleotides were annealed and ligated into the linearized pSIREN-Shuttle (Clontech). Each recombinant construct was sequenced to confirm the right sequence of insert. The construct contained siDKK1 sequence was designated as pSIREN-Shuttle-siDKK1, while the plasmid with scrambled sequence was named as pSIREN-Shuttle-Control.
For transfection, HepG2 and Bel7402 cells were seeded in 24-well plates at 5 × 104 per well and incubated at 37°C in a humidified incubator containing 5% CO2. The next day, when these cells were about 80% confluence, cells were transfected with TurboFect™ in vitro Transfection Reagent according to the manufacturer’s instructions. These transfected cells were selected with 0.1 mg/mL G418 for at least 2 weeks, and then the stable plasmid-transfected clones were generated by using limiting dilution analysis in 96-well plates. The clones derived from HepG2 cells stably transfected with pIRES2-EGFP-DKK1 or pIRES2-EGFP vector were classified as DKK1 and Vector respectively; whereas the clones derived from Bel7402 cells stably transfected with pSIREN-Shuttle-siDKK1 or pSIREN-Shuttle-Control were classified as shDKK1 and shControl respectively. For β-catenin and MMP7 transfections, tumor cells transiently transfected with human beta-catenin pcDNA3 (plasmid 16828; Addgene, Cambridge, MA), pcDNA3 (Invitrogen), pCMV6-XL5-MMP7 and pCMV6-XL5 (OriGene, USA) using TurboFect™ in vitro Transfection Reagent for 36 h, then were applied to other expriements.
Cell growth curve analysis
The MTT assay was used to detect the proliferation rate of tumor cells. Briefly, 2000 cells per well were plated in 96-well plates and incubated 1, 2, 3, 4, 5, 6 and 7d, respectively. At indicated time point, the process was performed as described before . Briefly, 50 μl of MTT reagent (1 mg/mL) was added and incubated for 4 h at 37°C in a humidified incubator containing 5% CO2. Supernatants were removed from the wells, and then 100 μl DMSO was added to solubilize the crystal products at room temperature for 10 min. The absorbance (OD) was measured with a microplate reader (Bio-Rad) at a wavelength of 570 nm.
RNA isolation and RT-PCR
For PCR, total RNA was extracted from sub-confluent using TRIzol reagent (Invitrogen). Two microgram of total RNA was subjected to DNase I digestion (1 U/μL, Fermentas, Hanover, MD) at 37°C for 30 min, and then the DNase I was heated inactivation at 70°C for 15 min, followed by reverse-transcription using PrimeScript™ Reverse Transcriptase (Takara). Semiquantitative RT-PCR was performed using primers listed in Additional file 1: Table S1. All PCR reactions were done using the following conditions: 95°C 5 min, 95°C 45 s, annealing at different temperatures for each gene respectively 45 s, extension 72°C 1 min for 30 cycles, and a final extension at 72°C for 10 min. All PCR products were separated by electrophoresis on 1.0% agarose gels.
Colony formation assay
The colony formation assay was performed as previously described with some modification . Briefly, a total of 400 cells every well were seeded into a fresh 6-well plate and incubated in RPMI1640 containing 10% FCS, cell medium was changed every 3 d for 15 d until visible colonies formed. Colonies were fixed with methanol and stained with 0.1% crystal violet in 20% methanol for 20 min. Microscopic colonies composed of more than 50 cells were counted in each well.
TCF luciferase reporter assay
HCC cells grown in 24-well plates were transiently transfected with M50 Super 8x TOPFlash with the wild-type TCF binding sites or its control M51 Super 8X FOPflash with the mutant TCF binding sites ((plasmid 12456 or plasmid 12457, Addgene, Cambridge, MA), in combination with pRL-TK (Renilla luciferase; Promega, Madison, WI) using TurboFect™ in vitro Transfection Reagent (Fermentas) according to the manufacturer’s instructions. After 36 h, the transfected cells were lysed and luciferase activity measurement was performed with the Dual-Luciferase Reporter Assay System (Promega).
Wound scratch assay
The wound scratch assay was performed as described previously . Briefly, cells were plated in a 24-well plate and grown to a confluence cell monolayer overnight prior to serum starvation for 24 h. After scratching with a pipette tip (20 μL); in order to eliminate the floating cells, culture medium was removed and wells were washed three times with PBS. The width of the wound was measured and recorded as t = 0. The cells were then allowed to migrated back into the wounded area, 24 h latter, the width of the open area was measured. Cell migration was expressed as the percentage of the gap (t = 24 h) relative to the primary width of the open area (t = 0 h). All experiments were performed in triplicate.
Cell migration and invasion assay
The migration and invasion assays were performed as in a 24-well Boyden chamber with 8 μm pore size polycarbonate membrane (Corning, NY, USA), as previously described . For migration assay, 200 μL of serum-free medium (containing 1 × 105 cells) was added to the upper compartment of the chamber, while the lower compartment was filled with 600 μL of RPMI 1640 supplemented with 10% FBS. After incubation at 37°C for 24 h, the tumor cells remaining inside the upper chamber were removed with cotton swabs. The cells on the lower surface of the membrane were stained with 0.1% crystal violet after fixation with methanol, and then counted under a light microscope. The invasion assay was done by the same procedure, except that the membrane was coated with Matrigel to form a matrix barrier, and 3 × 104 tumor cells were added to the upper chamber.
The immunofluorescence staining was carried out as previously described with some changes . Briefly, tumor cells were washed three times with ice-cold PBS, fixed in 4.0% paraformaldehyde. After permeabilization with 0.1% Triton X-100, cells were blocked of nonspecific binding by incubation with 5% normal goat serum in PBS. Afterwards, cells were incubated with the rabbit polyclonal β-catenin antibody overnight at 4°C. The staining was completed with Cy3-labeled goat anti-rabbit second antibody (1:500, Beyotime, China) incubation for 1 h at room temperature, and nuclei was counterstained with Hoechst33342 (10 μg/mL, Sigma, USA) for 30 min at dark. All photographs were taken by using High content screening (HCS) (Thermo Scientific Cellomics ArrayScan Vti, Cellomics, Inc., Pittsburgh, PA).
Western blot analysis
Western blot analysis was performed as our described previously . Briefly, cell pellets were washed thrice with ice-cold phosphate buffered saline (PBS) and were lysed with RIPA buffer (Beyotime, China). The total protein concentration was determined using a BCA assay kit (Beyotime, China). Samples were denatured in 5 × SDS-sample buffer at 95°C for 5 min. Equal amounts of total proteins were separated using 12% SDS-PAGE, and then transferred onto PVDF membranes. Membranes were then blocked by 5% dried skimmed milk in PBST at room temperature for 1 h. After blocking, membranes were incubated with corresponding primary antibodies overnight at 4 °C. After washed three times with PBST, the membranes were incubated with appropriate HRP-conjugated secondary antibody, and then washed three times with PBST. Proteins were detected by using the ECL plus reagents (Beyotime, China).
Immunohistochemical (IHC) staining
Formalin-fixed and Paraffin-embedded tissue sections were de-paraffinized in xylene, rehydrated through graded ethanol, quenched for endogenous peroxidase activity in 0.3% hydrogen peroxide, and processed for antigen retrieval in citrate buffer (pH 6.0) for 10 min by microwave heating. Following overnight incubation at 4°C using rabbit mAb against human DKK1 (1:200) or β-catenin (1:100). Immunostaining was performed with an optimal amount of HRP-conjugated secondary antibody for 1 h at room temperature and DAB was used as chromogen. Subsequently, sections were counterstained with hematoxylin.
DKK1 and β-catenin expression were evaluated under a light microscope at a magnification of 200×. For each specimen, five images of representative areas were acquired and tumor cells were counted. For human samples, IHC scoring was performed using a modified Histo-score (H-score) as described by Fang et al..
Data in this study were expressed as mean ± SEM from at least three separate experiments. Unless otherwise noted, the differences between groups were analyzed using Student’s t-test (two groups) or ANOVA (≥ three groups). All statistical analyses were performed using SPSS 13.0 software (Chicago, IL, USA). All tests employed were two-sided, and p <0.05 was set to be considered statistically significant.
DKK1 is overexpressed in human hepatocellular carcinoma cell lines
DKK1 overexpression did not influence the cell proliferation rate and colony formation
DKK1 promotes HCC cell migration and invasion
DKK1 regulates the expression of β-catenin
DKK1 exert its function by promoting β-catenin signaling
The role of β-catenin in DKK1-mediated phenotypes was then evaluated. First, we examined whether blockage of β-catenin could attenuated the effect of DKK1 expression. As expected, upon treatment with β-catenin inhibitor IWP-2, the promotive effect of DKK1 on migration and invasion was significantly attenuated in DKK1-transfectants, whereas there were no statistically significant differences in those of Vector-transfectants (Figure 4F and G). On the other hand, overexpression of β-catenin in shDKK1-transfectants restored the transcription of β-catenin (Figure 5C), and attenuated the inhibitory effect of shDKK1 on invasion (Figure 5D). As GSK3β is an important upstream target of β-catenin signaling, we further analyzed whether blockage of GSK3β could mimic the effect of β-catenin expression. Upon treatment with GSK3β inhibitor LiCl, the inhibitory effect of shDKK1 on migration (Figure 5E) and invasion (Figure 5F) was dramatically released.
MMP7 is an important target downstream of DKK1/β-catenin signaling pathway
In this work, we found that DKK1 is strongly overexpressed in both HCC cell lines and clinical HCC samples. The expression of DKK1 is positively associated with the migration and invasion, but did not influence the proliferation or colony formation of HCC. Mechanistically, we demonstrated that DKK1 promoted HCC cell migration and invasion by upregulating β-catenin/MMP7 pathway. During this manuscript in preparation, Tao et al. showed that increased DKK1 expression could promote HCC invasion and metastasis via up-regulation of RhoA and JNK expression and non-canonical Wnt pathway . Their results in combination with our findings in this study, revealed the significant role of DKK1 in HCC cell migration and invasion.
Recently, Shen et al. demonstrated that DKK1 as a serum biomarker can improve the diagnostic accuracy for HCC in a large-scale, multicenter study. Their study revealed that the levels of DKK1 in serum are significantly higher in patients with HCC than in all controls . In the present data, we found that DKK1 is expressed at high levels in 3 of 4 HCC cell lines in comparison with that of the control normal liver cell line. Furthermore, specific DKK1 was predominantly observed to be expressed in HCC tissues but not in the adjacent non-tumor liver tissues. All these findings indicated that DKK1 performs as an oncogenic factor rather than a tumor-suppressor in HCC.
Interestingly, in this study, we did not find that DKK1 expression influence HCC cell proliferation and colony formation, which are two of the most important features among the malignant cell behavior. While Qin et al. found that overexpression of DKK1 by transfection was able to inhibit the growth and migration in M-H7402 cells . One possible explanation is that the impact of DKK1 on cell proliferation may vary in different cell types. Because the tumor cells they used is a metastatic subclone of human HCC H7402 cells by isolating from transplantation of H7402 cells into severe combined immunodeficient (SCID) mice . In contrast, our experiments were performed by using two HCC cell lines, namely HepG2 and Bel7402.
Besides cell proliferation, migration and invasive capacity of cells are also two of the most important features of malignant cell behavior. Intriguingly, up-regulation of DKK1 significantly promoted HCC cell migration and invasion, vice versa, when DKK1 is repressed by a DKK1-specific shRNA, the tumor cell migration and invasion is markedly reduced. More importantly, in HCC tissues, the metastatic tumors showed much higher DKK1 expression comparison with that in the primary tumors. Consistent with our present data, Tung et al. found that knockdown of DKK1 significantly reduced both migratory and invasive abilities of the two independent SMMC7721 knockdown clones . Along the same line of arguments, Tao et al. reported that DKK1 could promote HCC invasion and metastasis in vitro and in vivo. Moreover, the increased expression of DKK1 closely correlates with multiple tumor nodes, high Edmondson-Steiner grade and vein invasion, as well as poor overall and disease-free survival of HCC . Taken together, our results in combined with the findings from others, suggesting that DKK1 plays an important role in promoting HCC cell migration and invasion.
Deregulation of Wnt/β-catenin signaling pathway is a hallmark of major gastrointestinal cancers including HCC . It is well-known that β-catenin is the chief effector downstream of this pathway. Approximately one third of HCCs have been reported to be associated with the aberrant expression of β-catenin . β-catenin plays a pivotal role in regulating the HCC development and tumorigenesis through its association with E-cadherin in cell-cell adhesion, interaction with the hepatocyte growth factor (HGF) receptor c-Met and regulation the canonical Wnt/β-catenin signaling pathway . DKK1 acts as a typical inhibitor of canonical Wnt/β-catenin pathway. Interestingly, several years ago, Yu et al. reported that the mRNA and protein expression levels of DKK1 are predominantly elevated in HCC. Moreover, the increased DKK1 expression is positively correlated with the total β-catenin accumulation in both HCC cell lines and clinical samples . Along the same line of argument, Xu et al. recently reported that up-regulation of DKK1 in their study significantly correlates with the cytoplasmic/nuclear β-catenin accumulation in triple negative breast cancers . Here, our data clearly suggested that DKK1 can directly promote tumor cell migration and invasion by stimulating β-catenin transcription and translation through a non-canonical Wnt signaling pathway in HCC cells. This conclusion is based on the following evidence. Firstly, DKK1 restoration not only markedly promotes both the level of β-catenin and β-catenin-dependent transcriptional activity, but also promotes the migration and invasion of HCC cells in vitro. Moreover, a positive relationship of DKK1 expression with β-catenin level was found in HCC tissues. Secondly, silencing of DKK1 not only significantly suppresses β-catenin expression and β-catenin-dependent transcriptional activity, but also attenuates the migration and invasion of HCC cells. Thirdly, neither the mRNA level of LRP6 nor the protein levels of LRP6 and GSK3β was affected by DKK1 expression.
MMP7, also known as matrilysin, is a secreted protein implicated in a broad range of extracellular matrix substrates destruction in various cancers. Additionally, MMP7 has been shown to play a crucial role for the invasive and metastatic potential of tumor cells [28, 29]. Recently, several reports have shown that MMP7 is overexpressed in both the cells and tissues of HCC [30, 31]. Moreover, it is well-known that MMP7 is one of the most important downstream target genes of β-catenin/TCF-4 . In some tissues, β-catenin transcriptionally regulates MMP7. For example, β-catenin activation induces the expression and secretion of MMP7 and promotes the binding of T cell factor to the MMP7 promoter in kidney epithelial cells, whereas delivery of the gene encoding DKK1 abolishes its induction . However, the relationship between MMP7 and DKK1 remain elusive in HCC. Here, we demonstrate MMP7 is an important target downstream of DKK1 in HCC cells, based on the following studies: overexpression of DKK1 or upon GSK3β inhibitor treatment is associated with enhanced level of MMP7, migration and invasion in HCC cells, whereas knockdown of DKK1 by shRNA represses MMP7 expression and inhibits migration and invasion of HCC cells. In addition, β-catenin inhibitor IWP-2 suppresses the protein level of MMP7 in a dose dependent manner and attenuates DKK1-mediated migration and invasion of HCC cells. All these findings suggested that DKK1 may enhance HCC cell migration and invasion by promoting β-catenin/MMP7 signaling pathway.
Taken together, our findings demonstrated that DKK1 promote HCC cell migration and invasion at least partly by promoting β-catenin/MMP7 signaling axis, which supports the notion that DKK1 could serve as a diagnostic biomarker for monitoring HCC development and progression. In addition, as DKK1 down-regulation can reduce the migration and invasion of HCC cells, it is a potential therapeutic strategy for advanced HCC.
This work was supported by NSFC-Henan talented man train union fund (No. U1204829) and Projects of Science and Technology of Henan (No.102300410095).
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010, 127: 2893-2917. 10.1002/ijc.25516View ArticlePubMedGoogle Scholar
- Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, Nashan B, Jücker M: Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer. 2012, 11: 85- 10.1186/1476-4598-11-85PubMed CentralView ArticlePubMedGoogle Scholar
- Yang Y, Nagano H, Ota H, Morimoto O, Nakamura M, Wada H, Noda T, Damdinsuren B, Marubashi S, Miyamoto A: Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery. 2007, 141: 196-202. 10.1016/j.surg.2006.06.033View ArticlePubMedGoogle Scholar
- Zorn AM: Wnt signalling: antagonistic Dickkopfs. Curr Biol. 2001, 11: R592-595. 10.1016/S0960-9822(01)00360-8View ArticlePubMedGoogle Scholar
- Seib DR, Corsini NS, Ellwanger K, Plaas C, Mateos A, Pitzer C, Celikel T, Martin-Villalba A: Loss of Dickkopf-1 restores neurogenesis in old age and counteracts cognitive decline. Cell Stem Cell. 2013, 12: 204-214. 10.1016/j.stem.2012.11.010View ArticlePubMedGoogle Scholar
- Pozzi S, Fulciniti M, Yan H, Vallet S, Eda H, Patel K, Santo L, Cirstea D, Hideshima T, Schirtzinge L: In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma. Bone. 2013, 53: 487-496. 10.1016/j.bone.2013.01.012PubMed CentralView ArticlePubMedGoogle Scholar
- Wang B, Liu J, Ma LN, Xiao HL, Wang YZ, Li Y, Wang Z, Fan L, Lan C, Yang M: Chimeric 5/35 adenovirus-mediated Dickkopf-1 overexpression suppressed tumorigenicity of CD44(+) gastric cancer cells via attenuating Wnt signaling. J Gastroenterol. 2013, 48: 798-808. 10.1007/s00535-012-0711-zView ArticlePubMedGoogle Scholar
- Shi RY, Yang XR, Shen QJ, Yang LX, Xu Y, Qiu SJ, Sun YF, Zhang X, Wang Z, Zhu K: High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery. Cancer. 2013, 119: 993-1003. 10.1002/cncr.27788View ArticlePubMedGoogle Scholar
- González-Sancho JM, Aguilera O, García JM, Pendás-Franco N, Peña C, Cal S, García De Herreros A, Bonilla F, Muñoz A: The Wnt antagonist DICKKOPF-1 gene is a downstream target of beta-catenin/TCF and is downregulated in human colon cancer. Oncogene. 2005, 24: 1098-1103. 10.1038/sj.onc.1208303View ArticlePubMedGoogle Scholar
- Sikandar S, Dizon D, Shen X, Li Z, Besterman J, Lipkin SM: The class I HDAC inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and non-canonical Wnt signaling. Oncotarget. 2010, 1: 596-605.PubMed CentralView ArticlePubMedGoogle Scholar
- Qi L, Sun B, Liu Z, Li H, Gao J, Leng X: Dickkopf-1 inhibits epithelial-mesenchymal transition of colon cancer cells and contributes to colon cancer suppression. Cancer Sci. 2012, 103: 828-835. 10.1111/j.1349-7006.2012.02222.xView ArticlePubMedGoogle Scholar
- Yamabuki T, Takano A, Hayama S, Ishikawa N, Kato T, Miyamoto M, Ito T, Ito H, Miyagi Y, Nakayama H: Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res. 2007, 67: 2517-2525. 10.1158/0008-5472.CAN-06-3369View ArticlePubMedGoogle Scholar
- Forget MA, Turcotte S, Beauseigle D, Godin-Ethier J, Pelletier S, Martin J, Tanguay S, Lapointe R: The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types. Br J Cancer. 2007, 96: 646-653. 10.1038/sj.bjc.6603579PubMed CentralView ArticlePubMedGoogle Scholar
- Qin X, Zhang H, Zhou X, Wang C, Zhang H, Zhang X, Ye L: Proliferation and migration mediated by Dkk-1/Wnt/beta-catenin cascade in a model of hepatocellular carcinoma cells. Transl Res. 2007, 150: 281-294. 10.1016/j.trsl.2007.06.005View ArticlePubMedGoogle Scholar
- Tao YM, Liu Z, Liu HL: Dickkopf-1 (DKK1) promotes invasion and metastasis of hepatocellular carcinoma. Dig Liver Dis. 2013, 45: 251-257. 10.1016/j.dld.2012.10.020View ArticlePubMedGoogle Scholar
- Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, Wang N, Niu Y, Wu Z, Zhou J: Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012, 13: 817-826. 10.1016/S1470-2045(12)70233-4View ArticlePubMedGoogle Scholar
- Tung EK, Mak CK, Fatima S, Lo RC, Zhao H, Zhang C, Dai H, Poon RT, Yuen MF, Lai CL: Clinicopathological and prognostic significance of serum and tissue Dickkopf-1 levels in human hepatocellular carcinoma. Liver Int. 2011, 31: 1494-1504. 10.1111/j.1478-3231.2011.02597.xView ArticlePubMedGoogle Scholar
- Xie SQ, Zhang YH, Li Q, Xu FH, Miao JW, Zhao J, Wang CJ: 3-Nitro-naphthalimide and nitrogen mustard conjugate NNM-25 induces hepatocellular carcinoma apoptosis via PARP-1/p53 pathway. Apoptosis. 2012, 17: 725-734. 10.1007/s10495-012-0712-7View ArticlePubMedGoogle Scholar
- Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP, Zhuang SM: MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology. 2009, 50: 113-121. 10.1002/hep.22919View ArticlePubMedGoogle Scholar
- Wong CC, Wong CM, Tung EK, Man K, Ng IO: Rho-kinase 2 is frequently overexpressed in hepatocellular carcinoma and involved in tumor invasion. Hepatology. 2009, 49: 1583-1594. 10.1002/hep.22836View ArticlePubMedGoogle Scholar
- Fang JH, Zhou HC, Zeng C, Yang J, Liu Y, Huang X, Zhang JP, Guan XY, Zhuang SM: MicroRNA-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression. Hepatology. 2011, 54: 1729-1740. 10.1002/hep.24577View ArticlePubMedGoogle Scholar
- Filipovich A, Gandhirajan RK, Gehrke I, Poll-Wolbeck SJ, Kreuzer KA: Evidence for non-functional Dickkopf-1 (DKK-1) signaling in chronic lymphocytic leukemia (CLL). Eur J Haematol. 2010, 85: 309-313. 10.1111/j.1600-0609.2010.01494.xView ArticlePubMedGoogle Scholar
- Nakachi S, Nakazato T, Ishikawa C, Kimura R, Mann DA, Senba M, Masuzaki H, Mori N: Human T-cell leukemia virus type 1 tax transactivates the matrix metalloproteinase 7 gene via JunD/AP-1 signaling. Biochim Biophys Acta. 1813, 2011: 731-741.Google Scholar
- Fatima S, Lee NP, Tsang FH, Kolligs FT, Ng IO, Poon RT, Fan ST, Luk JM: Dickkopf 4 (DKK4) acts on Wnt/beta-catenin pathway by influencing beta-catenin in hepatocellular carcinoma. Oncogene. 2012, 31: 4233-4244. 10.1038/onc.2011.580View ArticlePubMedGoogle Scholar
- Llovet JM, Bruix J: Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008, 48: 1312-1327. 10.1002/hep.22506PubMed CentralView ArticlePubMedGoogle Scholar
- Thompson MD, Monga SP: WNT/beta-catenin signaling in liver health and disease. Hepatology. 2007, 45: 1298-1305. 10.1002/hep.21651View ArticlePubMedGoogle Scholar
- Yu B, Yang X, Xu Y, Yao G, Shu H, Lin B, Hood L, Wang H, Yang S, Gu J, Fan J, Qin W: Elevated expression of DKK1 is associated with cytoplasmic/nuclear beta-catenin accumulation and poor prognosis in hepatocellular carcinomas. J Hepatol. 2009, 50: 948-957.View ArticlePubMedGoogle Scholar
- Oshima T, Akaike M, Yoshihara K, Shiozawa M, Yamamoto N, Sato T, Yamada R, Fujii S, Rino Y, Kunisaki C: Clinicopathological significance of the gene expression of matrix metalloproteinase-7, insulin-like growth factor-1, insulin-like growth factor-2 and insulin-like growth factor-1 receptor in patients with colorectal cancer: insulin-like growth factor-1 receptor gene expression is a useful predictor of liver metastasis from colorectal cancer. Oncol Rep. 2008, 20: 359-364.PubMedGoogle Scholar
- Ochiai H, Nakanishi Y, Fukasawa Y, Sato Y, Yoshimura K, Moriya Y, Kanai Y, Watanabe M, Hasegawa H, Kitagawa Y: A new formula for predicting liver metastasis in patients with colorectal cancer: immunohistochemical analysis of a large series of 439 surgically resected cases. Oncology. 2008, 75: 32-41. 10.1159/000151667View ArticlePubMedGoogle Scholar
- Gao Q, Wang XY, Qiu SJ, Zhou J, Shi YH, Zhang BH, Fan J: Tumor stroma reaction-related gene signature predicts clinical outcome in human hepatocellular carcinoma. Cancer Sci. 2011, 102: 1522-1531. 10.1111/j.1349-7006.2011.01981.xView ArticlePubMedGoogle Scholar
- Tomimaru Y, Koga H, Yano H, de la Monte S, Wands JR, Kim M: Upregulation of T-cell factor-4 isoform-responsive target genes in hepatocellular carcinoma. Liver Int. 2013, 33: 1100-1112. 10.1111/liv.12188PubMed CentralView ArticlePubMedGoogle Scholar
- He W, Tan RJ, Li Y, Wang D, Nie J, Hou FF, Liu Y: Matrix metalloproteinase-7 as a surrogate marker predicts renal Wnt/beta-catenin activity in CKD. J Am Soc Nephrol. 2012, 23: 294-304. 10.1681/ASN.2011050490PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.